Mirati Therapeutics Inc

Exclusive news, data and analytics for financial market professionalsLearn more about

Skip to main content

Company

Mirati Therapeutics Inc

13 results

Healthcare & PharmaceuticalscategoryU.S. new drug price exceeds $200,000 median in 2022, article with imageJanuary 5, 2023
United StatescategoryU.S. FDA approves Mirati's lung cancer drug, article with imageDecember 13, 2022
MarketscategoryS&P posts 4th straight decline as recession talk weighs on Wall Street, article with videoDecember 7, 2022
BusinesscategoryMirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patientsDecember 6, 2022
MarketscategoryMirati attracts fresh takeover interest - Bloomberg NewsNovember 22, 2022
Future of HealthcategoryAmgen says Lumakras cuts risk of lung cancer progression by 34%, article with imageSeptember 11, 2022
Future of HealthcategoryAmgen's Lumakras/immunotherapy combo data held for August lung cancer meeting, article with imageJuly 13, 2022
Healthcare & PharmaceuticalscategoryMirati drug helps some patients whose lung cancer spread to the brain, study says, article with imageJune 6, 2022
Future of HealthcategoryMirati lung cancer data disappoint, shares fall 21%May 26, 2022
MarketscategoryU.S. RESEARCH ROUNDUP Datadog, Home Depot, WalmartNovember 19, 2021
BusinesscategoryMirati Therapeutics taps industry veteran Meek as CEO, article with imageSeptember 20, 2021
BusinesscategoryMirati drug combination shrinks tumors in 39% of colon cancer patients in studySeptember 19, 2021
BusinesscategoryFDA approves Amgen drug for lung cancer with specific mutation, article with imageMay 28, 2021

1 to 13 of 13